September 25th 2024
A continuous increase in ASCVD risk was seen with higher levels of lipoprotein(a) in the largest study to date of the relationship.
Dyslipidemia: How Aggressively to Intervene in the Older Patient?
September 15th 2006ABSTRACT: Lipid abnormalities are extremely prevalent among the elderly, a group at very high risk for cardiovascular disorders. Accordingly, the treatment guidelines of the National Cholesterol Education Program Adult Treatment Panel do not suggest that lipid management be any less aggressive in older patients than in younger ones. Management decisions focus on the calculated low-density lipoprotein cholesterol level as part of a full fasting lipid panel. Dietary counseling remains an important element in the management of lipid disorders, but almost all elderly patients require medications to reach their lipid goals. The statins are the mainstay of treatment for most patients, but some will require additional agents, such as a fibrate, niacin, ezetimibe, fish oil, or a bile acid sequestrant.
Coronary Heart Disease and Dyslipidemia
September 15th 2006ABSTRACT: Lipid abnormalities are extremely prevalent among the elderly, a group at very high risk for cardiovascular disorders. Accordingly, the treatment guidelines of the National Cholesterol Education Program Adult Treatment Panel do not suggest that lipid management be any less aggressive in older patients than in younger ones. Management decisions focus on the calculated low-density lipoprotein cholesterol level as part of a full fasting lipid panel. Dietary counseling remains an important element in the management of lipid disorders, but almost all elderly patients require medications to reach their lipid goals. The statins are the mainstay of treatment for most patients, but some will require additional agents, such as a fibrate, niacin, ezetimibe, fish oil, or a bile acid sequestrant.
Subclinical Hypothyroidism: REFERENCES: EvidencE-based medicine: Relevant guidelines:
September 1st 2006ABSTRACT: Subclinical hypothyroidism is associated with elevated low-density lipoprotein (LDL) cholesterol levels and several factors related to atherosclerosis, including increased C-reactive protein levels and impaired endothelium-dependent vasodilatation. However, considerable controversy exists about screening for and treating this thyroid disorder. Thyroxine therapy lowers elevated LDL cholesterol levels in patients whose serum thyroid-stimulating hormone (TSH) concentrations are higher than 10 mIU/L ; thus, most experts recommend treatment for such patients. However, there is no consensus regarding the management of patients with TSH levels of less than 10 mIU/L. Although the evidence supporting treatment of these patients is not compelling, it is reasonable to offer a therapeutic trial of thyroxine to those who have symptoms.
Barriers to Care in Chronic Disease: How to Bridge the Treatment Gap
September 1st 2006ABSTRACT: Our knowledge of chronic diseases has advanced significantly in recent decades, but patient outcomes have not kept pace. This is largely because the traditional acute care model does not adequately address the needs of patients with chronic disease. Patients play an active role in the management of chronic disease, and successful outcomes are highly dependent on adherence to treatment. Thus, clinicians need to have skills in coaching and encouraging as well as an awareness of factors in patients' backgrounds that are likely to affect their ability or willingness to follow treatment plans. Provider- and system-related factors, such as lack of reimbursement for counseling and high copayments, can also act as barriers to compliance. Among the strategies that can improve adherence are the use of community resources, multidisciplinary approaches, and regular follow-up.
OTC Statins: The Debate Continues
September 1st 2006The recent editorial by David T. Nash, MD, "OTC Statins: Panacea or Pandora's Box?" (CONSULTANT, July 2006, page 845), prompted a number of readers to write in. A selection of the comments received, along with a response from Dr Nash, appears below. Additional comments appear on www.ConsultantLive.com.
Barriers to Care in Chronic Disease: How to Bridge the Treatment Gap
September 1st 2006Over the past few decades, the management of chronic disease has assumed a greater role in health care. Diseases such as diabetes, chronic obstructive pulmonary disease, and depression have replaced acute disorders as the leading cause of morbidity, mortality, and health care expenditures.